Equities Research Analysts’ Updated EPS Estimates for June 18th (ADSK, AMRN, AON, ASCL, AZN, BHVN, BP, BWY, BXMT, CATX)

Equities Research Analysts’ updated eps estimates for Tuesday, June 18th:

Autodesk (NASDAQ:ADSK) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $260.00 target price on the stock.

Autodesk (NASDAQ:ADSK) had its outperform rating reissued by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $275.00 price target on the stock.

Amarin (NASDAQ:AMRN) had its overweight rating reissued by analysts at Cantor Fitzgerald.

AON (NYSE:AON) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $315.00 price target on the stock.

Ascential (LON:ASCL) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a GBX 433 ($5.50) target price on the stock.

AstraZeneca (LON:AZN) had its hold rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a £110 ($139.77) target price on the stock.

Biohaven (NYSE:BHVN) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $59.00 price target on the stock.

BP (LON:BP) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a GBX 650 ($8.26) price target on the stock.

Bellway (LON:BWY) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a GBX 3,650 ($46.38) target price on the stock.

Blackstone Mortgage Trust (NYSE:BXMT) had its market perform rating reissued by analysts at Keefe, Bruyette & Woods. The firm currently has a $18.00 target price on the stock.

Perspective Therapeutics (NYSE:CATX) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

Perspective Therapeutics (NYSE:CATX) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc..

Cognyte Software (NASDAQ:CGNT) had its hold rating reiterated by analysts at Needham & Company LLC.

Chemring Group (LON:CHG) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a GBX 450 ($5.72) price target on the stock.

Chegg (NYSE:CHGG) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Celldex Therapeutics (NASDAQ:CLDX) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $67.00 target price on the stock.

Clene (NASDAQ:CLNN) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $7.00 price target on the stock.

CMC Markets (LON:CMCX) had its sell rating reaffirmed by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a GBX 192 ($2.44) price target on the stock.

Coinbase Global (NASDAQ:COIN) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $315.00 target price on the stock.

CoStar Group (NASDAQ:CSGP) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $110.00 price target on the stock.

DigitalBridge Group (NYSE:DBRG) had its buy rating reissued by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a $17.00 target price on the stock, down from their previous target price of $21.00.

Dynatrace (NYSE:DT) had its hold rating reissued by analysts at Needham & Company LLC.

Editas Medicine (NASDAQ:EDIT) had its market perform rating reiterated by analysts at Oppenheimer Holdings Inc.. The firm currently has a $12.00 target price on the stock.

Franklin Covey (NYSE:FC) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $45.00 price target on the stock.

GSK (LON:GSK) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a GBX 1,950 ($24.78) target price on the stock.

GSK (LON:GSK) had its underweight rating reiterated by analysts at JPMorgan Chase & Co..

Hikma Pharmaceuticals (LON:HIK) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 2,750 ($34.94) price target on the stock.

Holley (NYSE:HLLY) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $12.00 target price on the stock.

Horace Mann Educators (NYSE:HMN) had its market perform rating reaffirmed by analysts at JMP Securities.

HomeStreet (NASDAQ:HMST) had its market perform rating reissued by analysts at Keefe, Bruyette & Woods. They currently have a $13.50 price target on the stock.

International Consolidated Airlines Group (LON:IAG) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a GBX 230 ($2.92) price target on the stock.

Immunovant (NASDAQ:IMVT) had its overweight rating reissued by analysts at Cantor Fitzgerald.

Inchcape (LON:INCH) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a GBX 1,100 ($13.98) target price on the stock.

Incyte (NASDAQ:INCY) had its neutral rating reissued by analysts at Cantor Fitzgerald.

Jasper Therapeutics (NASDAQ:JSPR) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

KalVista Pharmaceuticals (NASDAQ:KALV) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $35.00 price target on the stock.

Kimberly-Clark (NYSE:KMB) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $165.00 price target on the stock.

CarMax (NYSE:KMX) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $90.00 price target on the stock.

Keros Therapeutics (NASDAQ:KROS) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $100.00 target price on the stock.

Kura Oncology (NASDAQ:KURA) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $32.00 target price on the stock.

Lennar (NYSE:LEN) had its underperform rating reaffirmed by analysts at Wedbush. They currently have a $144.00 target price on the stock.

Lennar (NYSE:LEN) had its outperform rating reaffirmed by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $183.00 price target on the stock.

Merck & Co., Inc. (NYSE:MRK) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $155.00 target price on the stock.

Marinus Pharmaceuticals (NASDAQ:MRNS) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $11.00 target price on the stock.

NiSource (NYSE:NI) had its outperform rating reissued by analysts at BMO Capital Markets. BMO Capital Markets currently has a $31.00 target price on the stock.

ServiceNow (NYSE:NOW) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $900.00 price target on the stock.

Intellia Therapeutics (NASDAQ:NTLA) had its overweight rating reissued by analysts at Cantor Fitzgerald. They currently have a $65.00 price target on the stock.

Oxford BioDynamics (LON:OBD) had its house stock rating reaffirmed by analysts at Shore Capital.

ON (NYSE:ONON) had its buy rating reaffirmed by analysts at Truist Financial Co.. They currently have a $46.00 price target on the stock.

Orrstown Financial Services (NASDAQ:ORRF) had its outperform rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $32.00 price target on the stock.

Primo Water (NYSE:PRMW) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $30.00 price target on the stock.

PolyPid (NASDAQ:PYPD) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $14.00 target price on the stock.

Q2 (NYSE:QTWO) had its buy rating reissued by analysts at Truist Financial Co.. They currently have a $68.00 price target on the stock, up from their previous price target of $65.00.

Rio Tinto Group (LON:RIO) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a GBX 6,200 ($78.78) target price on the stock.

Roivant Sciences (NASDAQ:ROIV) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald.

RS Group (LON:RS1) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a GBX 780 ($9.91) price target on the stock.

Synectics (LON:SNX) had its house stock rating reissued by analysts at Shore Capital.

SThree (LON:STEM) had its buy rating reissued by analysts at Berenberg Bank. They currently have a GBX 550 ($6.99) price target on the stock.

Tapestry (NYSE:TPR) had its buy rating reiterated by analysts at Argus. The firm currently has a $52.00 target price on the stock.

TriplePoint Venture Growth BDC (NYSE:TPVG) had its underperform rating reissued by analysts at Keefe, Bruyette & Woods. The firm currently has a $9.00 price target on the stock.

Videndum (LON:VID) had its hold rating reiterated by analysts at Shore Capital.

WD-40 (NASDAQ:WDFC) had its buy rating reiterated by analysts at DA Davidson. They currently have a $313.00 target price on the stock.

Whitbread (LON:WTB) had its buy rating reiterated by analysts at Shore Capital.

Xenon Pharmaceuticals (NASDAQ:XENE) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $55.00 price target on the stock.

Zillow Group (NASDAQ:ZG) had its buy rating reaffirmed by analysts at DA Davidson. DA Davidson currently has a $52.00 price target on the stock.

Zuora (NYSE:ZUO) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $15.00 price target on the stock.

Receive News & Ratings for Autodesk Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autodesk Inc and related companies with MarketBeat.com's FREE daily email newsletter.